KR20100071397A - Healthy food composition containing the cactus extract for non-toxic, antioxidant active and antiobese active - Google Patents
Healthy food composition containing the cactus extract for non-toxic, antioxidant active and antiobese active Download PDFInfo
- Publication number
- KR20100071397A KR20100071397A KR1020080130097A KR20080130097A KR20100071397A KR 20100071397 A KR20100071397 A KR 20100071397A KR 1020080130097 A KR1020080130097 A KR 1020080130097A KR 20080130097 A KR20080130097 A KR 20080130097A KR 20100071397 A KR20100071397 A KR 20100071397A
- Authority
- KR
- South Korea
- Prior art keywords
- cactus
- extract
- kumho
- activity
- antioxidant
- Prior art date
Links
- 241000219357 Cactaceae Species 0.000 title claims abstract description 133
- 239000000284 extract Substances 0.000 title claims abstract description 132
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 26
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 25
- 231100000252 nontoxic Toxicity 0.000 title claims abstract description 20
- 230000003000 nontoxic effect Effects 0.000 title claims abstract description 20
- 235000001497 healthy food Nutrition 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 230000003579 anti-obesity Effects 0.000 claims abstract description 22
- 235000013402 health food Nutrition 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 235000020510 functional beverage Nutrition 0.000 claims description 22
- 239000012141 concentrate Substances 0.000 claims description 11
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 22
- 235000004727 Opuntia ficus indica Nutrition 0.000 abstract description 4
- 241000883559 Echinocactus grusonii Species 0.000 abstract description 3
- 240000001439 Opuntia Species 0.000 abstract description 3
- 240000009297 Opuntia ficus-indica Species 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 229930091371 Fructose Natural products 0.000 description 20
- 239000005715 Fructose Substances 0.000 description 20
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 20
- 239000007788 liquid Substances 0.000 description 20
- 235000006708 antioxidants Nutrition 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 102000019280 Pancreatic lipases Human genes 0.000 description 16
- 108050006759 Pancreatic lipases Proteins 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 230000035772 mutation Effects 0.000 description 15
- 229940116369 pancreatic lipase Drugs 0.000 description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 14
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 14
- 229930003268 Vitamin C Natural products 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 235000019154 vitamin C Nutrition 0.000 description 14
- 239000011718 vitamin C Substances 0.000 description 14
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 13
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 13
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 235000012907 honey Nutrition 0.000 description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 9
- 229940109850 royal jelly Drugs 0.000 description 9
- 239000000811 xylitol Substances 0.000 description 9
- 235000010447 xylitol Nutrition 0.000 description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 9
- 229960002675 xylitol Drugs 0.000 description 9
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 8
- 229960002401 calcium lactate Drugs 0.000 description 8
- 239000001527 calcium lactate Substances 0.000 description 8
- 235000011086 calcium lactate Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- BEFAQJJPFPNXIG-UHFFFAOYSA-N 1-nitro-9h-fluorene Chemical compound C1C2=CC=CC=C2C2=C1C([N+](=O)[O-])=CC=C2 BEFAQJJPFPNXIG-UHFFFAOYSA-N 0.000 description 7
- CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical compound C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 7
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003471 mutagenic agent Substances 0.000 description 7
- 231100000707 mutagenic chemical Toxicity 0.000 description 7
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 7
- 229940117972 triolein Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 235000019626 lipase activity Nutrition 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 230000002790 anti-mutagenic effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000233805 Phoenix Species 0.000 description 4
- 208000010040 Sprains and Strains Diseases 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 230000002072 anti-mutant effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 244000237257 sweet prickly pear Species 0.000 description 4
- 230000002537 thrombolytic effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 241001091575 Echeveria Species 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010024453 Ligament sprain Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000007886 mutagenicity Effects 0.000 description 3
- 231100000299 mutagenicity Toxicity 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036560 skin regeneration Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001074093 Echinopsis Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000221537 Gymnocalycium mihanovichii Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- VPSXHKGJZJCWLV-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylpiperidin-4-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCN(CC1)CC VPSXHKGJZJCWLV-UHFFFAOYSA-N 0.000 description 1
- IKOKHHBZFDFMJW-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2-morpholin-4-ylethoxy)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCCN1CCOCC1 IKOKHHBZFDFMJW-UHFFFAOYSA-N 0.000 description 1
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001495482 Aeonium arboreum Species 0.000 description 1
- 241000162698 Aeonium decorum Species 0.000 description 1
- 241000347213 Aloe perfoliata Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000942087 Crassula capitella Species 0.000 description 1
- 241001660917 Crassula ovata Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001037738 Haworthiopsis fasciata Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241001091572 Kalanchoe Species 0.000 description 1
- 241001091573 Kalanchoe daigremontiana Species 0.000 description 1
- 241001600501 Kalanchoe tomentosa Species 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 235000000039 Opuntia compressa Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000304370 Orostachys Species 0.000 description 1
- 208000001715 Osteoblastoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038490 Renal pain Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940060515 aleve Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- -1 baeknyeoncho Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009750 upstream signaling Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/20—Synthetic spices, flavouring agents or condiments
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/6422—Xylitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Non-Alcoholic Beverages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 선인장 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물과 이의 제조방법에 관한 것으로, 더욱 상세하게는 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장으로부터 추출한 선인장 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물과 기능성 음료조성물 및 상기의 선인장 추출물을 추출하는 단계를 포함하는 건강식품조성물의 제조방법과 기능성 음료조성물의 제조방법에 관한 것이다. The present invention relates to a health food composition having a non-toxic, antioxidant and anti-obesity activity containing a cactus extract and a method for preparing the same, and more specifically, a cactus extracted from any one cactus selected from the group consisting of bogeum, daekyung and kumho. It relates to a health food composition and a functional beverage composition having a non-toxic, antioxidant and anti-obesity activity containing the extract and a method for producing a health food composition comprising the step of extracting the cactus extract.
선인장은 쌍떡잎식물 선인장목 선인장과에 속하는 식물을 총칭하는 것으로, 대개 잎이 없는 다육질의 큰 줄기가 특징인 현화식물이다. 한국에서 흔히 자라는 선인장(Opuntia ficus-indica var. saboten)은 열대산으로 높이 2m에 달하고 편평한 가지가 많이 갈라지며 제주도에서 자란다. 경절(莖節)은 짙은 녹색이고, 모양은 타원형 또는 달걀을 거꾸로 세운 모양이며 편평하다. 길이 1∼3cm의 가시가 2∼5개씩 돋고 바로 옆에 털이 있으나 오래된 것은 나무처럼 굵어지며 편평한 가지가 사방으로 퍼진다. 여름에 경절 윗가장자리에서 황색 꽃이 핀다. 꽃받침조각, 꽃잎 및 수술이 많고 암술은 1개이다. 씨방은 하위이고 열매는 장과로서 서양배같이 생기고 많은 종자가 들어 있으며 먹을 수 있으나 약용하거나 열대지방에서는 대부분 새들이 먹는다.Cactus is a generic name for plants belonging to the dicotyledonous cactus Cactus family, and it is a flowering plant that is characterized by fleshy large stems without leaves. Cactus (Opuntia ficus-indica var.saboten), which is common in Korea, is a tropical mountain, 2m high, with many flat branches, growing on Jeju Island. The femur is dark green, and the shape is elliptical or the egg upside down and is flat. 2 ~ 5 spines of 1-3cm long, with hairs next to them, but old ones become thick like trees and flat branches spread out in all directions. In summer, yellow flowers grow on the upper edge of the ganglia. Calyxes, petals, and stamens are many, with one pistil. The ovary is the lower part, and the fruit is berry, which looks like a pear, contains many seeds, and can be eaten, but is medicinal or mostly eaten by birds in the tropics.
우리나라에서는 90년대에 들어 손바닥 선인장을 이용한 각종 건강식품이 개발되면서 그 용도는 더욱 다양화 되었고, 약용과 식용을 동시에 만족하게 하는 식물로 자리하였다. 특히 통증, 종기, 비장비대의 초기치료, 신장 및 위의 통증완화, 뱀독의 해독, 해열 진정, 인후통 완화, 화상치료, 급성경기의 진정, 소염해독 작용, 급성 유선염 치료, 굳은살 제거, 기(氣)의 흐름과 혈액순환의 촉진, 어혈제거, 지사효과, 장염치료 등에서는 이미 민간요법으로 인정받아 온 것이기 때문에 발전 가능성은 더욱 큰 것이다. 또한 선인장 연구가 가장 활발한 멕시코에서는 당료 치료제로 캡슐 및 정제약의 개발을 비롯하여 많은 연구가 이루어져 있다. 또한 예로부터 농부들이 피곤하거나 목이 마를 때 선인장 줄기나 열매를 먹고 놀라울 정도로 회복이 빨라 정력제로 인기가 높으며, 여성들 사이에서는 다이어트와 피부미용제 및 변비 치료제로 각광을 받고 있다. 미국에서도 심장병 및 성인병 예방에 효능이 있는 것으로 알려져 있으며, 2년마다 세계적인 학술회의를 개최하는 등 활발한 연구가 진행되고 있다.In Korea, since the development of various health foods using palm cactus in the 90s, its use has been diversified, and it has become a plant that satisfies both medicinal and edible at the same time. In particular, pain, boils, early treatment of non-equipment, relieves kidney and stomach pain, detoxification of snake venom, antipyretic relief, sore throat relief, burn treatment, soothing acute symptoms, anti-inflammatory action, treatment of acute mastitis, callus removal, I) The possibility of development is even greater because it is already recognized as a folk remedy in the flow of blood, the promotion of blood circulation, the elimination of blood, the effect of the branch office, and the treatment of enteritis. In Mexico, where research on cactus is most active, many studies have been conducted, including the development of capsules and tablets as a medicinal treatment. In addition, farmers eat cactus stems or berries when they are tired or thirsty, and are recovering surprisingly fast. They are popular as energetics, and women are gaining attention as diets, skin care agents, and constipation treatments. It is known to be effective in preventing heart disease and adult disease in the United States, and active research is being conducted, such as a worldwide academic conference every two years.
특히 인슐린에 의존하지 않는 당뇨병 환자는 줄기를 섭취하여 혈당을 줄일 수 있는 것으로 알려져 있으며, 당이 많은 조건에서도 인슐린 활성을 증가시켜 당 함량을 줄여 준다는 것이다. 또한 혈액 내 저밀도 지질 단백질과 콜레스테롤, 트리글리세라이드의 함량을 줄일 수 있어 작물로서 큰 잠재력을 갖고 있다. 또한 손바닥 선인장이 도표에서 처럼 다른 채소나 과일에 비해 식이섬유와 같은 성분이 많이 들어 있어 변비예방과 장 운동의 활성화에 큰 효과가 있는 것으로 분석됐다. 또한 인간의 노화억제 및 암발생과 밀접한 관계를 갖고 있는 페놀성 물질과 플라보노이드 함유율이 생강, 칡뿌리에 비해 훨씬 많게 나타나고 있으며, 변비예방과 장의 활성화에 관여하는 식이섬유 함유율도 곡류, 신선채소류, 과실류에 비해 월등히 많이 함유되어 있고, 비타민C 또한 많이 함유되어 있는 것으로 밝혀져 음료 및 가공식품, 의약품 등이 개발될 가능성은 그만큼 크다 할 수 있다.In particular, diabetics who do not rely on insulin are known to be able to reduce their blood sugar by ingesting stems and reducing their sugar content by increasing insulin activity even in high sugar conditions. In addition, it can reduce the contents of low-density lipid protein, cholesterol, and triglycerides in the blood, which has great potential as a crop. In addition, palm cactus contains more ingredients such as dietary fiber than other vegetables and fruits as shown in the chart, and it is analyzed that it is effective in preventing constipation and activating bowel movement. In addition, the content of phenolic substances and flavonoids, which are closely related to human aging and cancer development, are much higher than that of ginger and rootroot, and the dietary fiber content involved in preventing constipation and intestinal activation is also high in grains, fresh vegetables, and fruits. Compared with much higher than that, vitamin C is also found to contain a lot of drinks, processed foods, pharmaceuticals, etc. can be developed that much.
상기의 여러가지 효능을 가진 선인장에 대한 연구는 이미 많이 밝혀져 있으며, 선인장을 이용한 젬, 젤리, 쥬스, 기타 가공품으로의 식품에의 응용 및 항암제, 혈당강하제, 항염증 및 진통제 등의 약용에의 응용도 활발히 연구가 되고 있는 실정이다. 따라서 선인장을 이용한 보다 다양한 응용분야 및 아직 밝혀지지 않은 새로운 효능의 연구와 개발이 필요하다. A lot of studies on cactus having various effects have already been made, and the application to foods such as gems, jelly, juice, and other processed products using cactus and its application to medicinal products such as anticancer agents, hypoglycemic agents, anti-inflammatory and analgesics The situation is being actively researched. Therefore, more diverse applications using cactus and the research and development of new efficacy that have not yet been identified are needed.
본 발명의 목적은 기존에 알려진 선인장의 효능과는 다르거나 더욱 우수한 효과를 가지는 선인장 추출물을 제공하고자 함이며, 그러한 우수한 효과를 가지는 선인장 추출물을 이용한 음료 및 이의 제조방법을 제공하고자 함이다.An object of the present invention is to provide a cactus extract having a different effect or better than the conventionally known efficacy of cactus, and to provide a beverage and a method for producing the same using a cactus extract having such an excellent effect.
상기의 과제를 해결하고자, To solve the above problems,
본 발명은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장으로부터 추출한 선인장 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물을 제공하며, 상기 선인장 추출물을 포함하는 기능성 음료조성물을 제공한다.The present invention provides a health food composition having a non-toxic, antioxidant and anti-obesity activity containing a cactus extract extracted from any one selected from the group consisting of bogeum, daekyung and kumho, and functional beverage composition comprising the cactus extract To provide.
또한 본 발명은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장으로부터 선인장 추출물을 추출하는 단계를 포함하는 것을 특징으로 하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물의 제조방법을 제공하며, 상기의 방법으로 제조된 선인장 추출물을 첨가하는 단계를 포함하는 것을 특징으로 하는 기능성 음료조성물의 제조방법을 제공한다.In another aspect, the present invention provides a method for producing a health food composition having a non-toxic, antioxidant and anti-obesity activity, characterized in that it comprises the step of extracting the cactus extract from any one cactus selected from the group consisting of bogeum, Daekyung and Kumho. And it provides a method for producing a functional beverage composition comprising the step of adding a cactus extract prepared by the above method.
본 발명의 선인장 추출물을 함유하는 조성물은 독성이 없어 안전할 뿐만 아 니라 항산화 및 항비만의 기능을 갖는 건강식품으로서의 역할을 하며, 선인장 추출물을 포함하는 맛과 영양이 우수한 기능성 음료조성물을 제공한다. 또한 선인장 추출물의 효율적 추출방법을 제공하며, 이를 응용한 다양한 식품산업에의 적용에도 이바지 할 수 있을 것으로 기대된다. The composition containing the cactus extract of the present invention is not toxic and safe as well as serves as a health food having the function of antioxidant and anti-obesity, and provides a functional beverage composition with excellent taste and nutrition containing cactus extract. In addition, it provides an efficient extraction method of cactus extract, and is expected to contribute to the application to various food industries using this.
본 발명은 보검(Opuntia ficus-indica P.Miller), 대경(Opuntia spec) 및 금호(Echinocactus grusonii)로 이루어진 군에서 선택된 어느 하나의 선인장으로부터 추출한 선인장 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물을 제공한다.The present invention provides a non-toxic, antioxidant and anti-obesity activity containing cactus extract extracted from any one cactus selected from the group consisting of Opuntia ficus-indica P. Miller , Opuntia spec and Kumho ( Echinocactus grusonii ). Eggplant provides a health food composition.
본 발명에서 상기 선인장 추출물은 정제수 또는 알코올 중에서 선택된 어느 하나 이상의 용매를 선인장 부피의 8~12배로 가하고 6~10시간 동안 80~100℃에서 추출하고, 상기 추출물을 농축하여 60~80 Brix 로 농축시킨 선인장 농축액일 수 있다.In the present invention, the cactus extract is added to any one or more solvents selected from purified water or alcohol to 8 to 12 times the volume of the cactus and extracted at 80 ~ 100 ℃ for 6 to 10 hours, the extract was concentrated to 60 to 80 Brix Cactus concentrate.
또한 본 발명은 상기 선인장 추출물을 포함하는 것을 특징으로 하는 기능성 음료조성물을 제공한다.The present invention also provides a functional beverage composition comprising the cactus extract.
본 발명은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장으로부터 선인장 추출물을 추출하는 단계를 포함하는 것을 특징으로 하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물의 제조방법을 제공한다.The present invention provides a method for producing a health food composition having a non-toxic, antioxidant and anti-obesity activity, comprising extracting a cactus extract from any one cactus selected from the group consisting of bogeum, daegyeong and kumho. .
본 발명에서 상기 제조방법은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장을 세척 및 절단하여 준비하는 단계;와 상기 준비된 선인장에 정제수 또는 알코올 중에서 선택된 어느 하나 이상의 용매를 선인장 부피의 8~12배로 가하고, 6~10시간 동안 80~100℃에서 추출하여 선인장 추출물을 얻는 단계; 및 상기 선인장 추출물을 60~80 Brix 로 농축시켜 선인장 농축액을 얻는 단계;를 포함할 수 있다.In the present invention, the manufacturing method comprises the steps of preparing and washing and cutting any one of the cactus selected from the group consisting of bogeum, large diameter and Kumho; and at least one solvent selected from purified water or alcohol in the prepared
또한 본 발명은 상기 방법으로 제조된 선인장 추출물을 첨가하는 단계를 포함하는 것을 특징으로 하는 기능성 음료조성물의 제조방법을 제공한다.In another aspect, the present invention provides a method for producing a functional beverage composition comprising the step of adding a cactus extract prepared by the above method.
이하 본 발명의 선인장 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물과 상기 선인장 추출물을 이용한 기능성 음료조성물 및 이들 건강식품조성물과 기능성 음료조성물의 제조방법에 대하여 상세하게 설명한다.Hereinafter, a health food composition having a non-toxic, antioxidant and anti-obesity activity containing the cactus extract of the present invention, a functional beverage composition using the cactus extract, and a method of preparing these health food compositions and functional beverage compositions will be described in detail.
본 발명은 고양시에서 대량 재배되고 있는 선인장을 가공식품 및 그 원료로 개발하기 위하여 선인장이 가지고 있는 생리활성과 식품으로서의 안정성을 검증하고, 이를 통하여 선택된 안정성이 보장되고 생리활성이 높은 선인장을 이용한 기능성 식품에 관한 것이다. 또한 본 발명은 이미 알려진 공지의 효능 이외에 아직 알려지지 않은 선인장의 효능을 구체적인 데이터에 의하여 증명하기 위한 실시예 및 실험예와, 이러한 유용적 기능을 가진 선인장의 추출물을 이용한 음료와 이의 제조방법에 관한 것이다.The present invention verifies the physiological activity and stability of the cactus in order to develop a cactus grown in Goyang as a processed food and its raw materials, and through this, functional food using a cactus having high physiological activity is ensured. It is about. In addition, the present invention relates to examples and experimental examples for proving the efficacy of cactus, which is not yet known, in addition to the known known effects, and beverages using the extract of the cactus having such a useful function and a method of preparing the same. .
본 발명은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인 장으로부터 추출한 선인장 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물을 제공한다. 선인장의 종류에는 화제, 정야, 당인, 십이지권, 와송, 염좌, 일월금, 흑법사, 월토이, 연보, 불사조, 불야성, 부용, 청솔, 백년초, 산취, 비목단 및 삼각주 등이 있으나, 본 발명의 효과인 비독성, 항산화 및 항비만 활성을 나타내는 선인장은 상기 보검, 대경 및 금호라 할 수 있다.The present invention provides a health food composition having a non-toxic, antioxidant and anti-obesity activity containing a cactus extract extracted from any one selected from the group consisting of bogeum, Daekyung and Kumho. Types of cactus include topic, night, Dangin, duodenum, wasong, sprain, sun moon gold, black temple, waltoy, annual report, phoenix, wildness, bouillon, blue sol, baeknyeoncho, acid odor, non-wood and delta, etc. Cactus showing non-toxic, antioxidant and anti-obesity activity, which are the effects of, may be referred to as Bogeum, Daekyung and Kumho.
본 발명에서 상기 선인장 추출물은 정제수 또는 알코올 중에서 선택된 어느 하나 이상의 용매를 선인장 부피의 8~12배로 가하고 6~10시간 동안 80~100℃에서 추출하고, 상기 추출물을 농축하여 60~80 Brix 로 농축시킨 선인장 농축액일 수 있다. In the present invention, the cactus extract is added to any one or more solvents selected from purified water or alcohol to 8 to 12 times the volume of the cactus and extracted at 80 ~ 100 ℃ for 6 to 10 hours, the extract was concentrated to 60 to 80 Brix Cactus concentrate.
바람직하게는 상기 선인장 추출물은 정제수 및 알코올을 95:5의 비율로 혼합한 용매를 선인장 부피의 10배로 가하고 8시간 동안 90℃에서 추출하여 선인장 추출물을 얻고, 상기 추출물을 농축하여 70 Brix 로 농축시킨 선인장 농축액일 수 있다. Preferably, the cactus extract is obtained by adding 10 times the volume of the cactus to a solvent mixed with purified water and alcohol at a ratio of 95: 5, extracting at 90 ° C. for 8 hours to obtain a cactus extract, and concentrating the extract to 70 Brix. Cactus concentrate.
또한 본 발명은 상기의 선인장 추출물을 포함하는 것을 특징으로 하는 기능성 음료조성물을 제공한다. 본 발명은 보검, 대경, 금호가 가지고 있는 항산화 및 항비만 활성과 비독성의 효능을 지닌 음료조성물을 제공함으로써 이를 음용하는 일반 국민들의 건강향상에도 기여할 수 있다. The present invention also provides a functional beverage composition comprising the cactus extract. The present invention can contribute to the improvement of health of the general public who drink it by providing a beverage composition having the antioxidant and anti-obesity activity and non-toxic efficacy of Bogeum, Daegyeong, and Kumho.
상기 선인장 추출물을 포함하는 기능성 음료조성물은 액상과당, 벌꿀, 로얄제리추출물, 구연산, 젖산칼슘, 비타민 C, 향료(스테비텐후레쉬), 자일리톨 및 정제수를 더 포함할 수 있다. 이러한 구성요소 이외에도 기능성 음료에 첨가되는 일 반적인 첨가물을 더 포함할 수 있다.The functional beverage composition containing the cactus extract may further include liquid fructose, honey, royal jelly extract, citric acid, calcium lactate, vitamin C, flavoring (stevitene fresh), xylitol, and purified water. In addition to these components it may further comprise a general additive added to the functional beverage.
바람직하게는 상기의 기능성 음료조성물은 음료조성물 전체중량 대비, 선인장 추출물 1~10중량%, 액상과당 10~20중량%, 벌꿀 0.5~1.0중량%, 로얄제리추출물 0.5~1.0중량%, 구연산 0.05~0.15중량%, 젖산칼슘 0.05~0.15중량%, 비타민 C 0.01~0.05중량%, 향료(스테비텐후레쉬) 0.01~0.03중량%, 자일리톨 0.1~0.5중량% 및 잔부의 정제수를 포함할 수 있다.Preferably, the functional beverage composition is 1 to 10% by weight of cactus extract, 10 to 20% by weight of liquid fructose, honey 0.5 to 1.0% by weight, royal jelly extract 0.5 to 1.0% by weight, citric acid 0.05 ~ 0.15% by weight, calcium lactate 0.05 ~ 0.15% by weight, vitamin C 0.01 ~ 0.05% by weight, fragrance (stebiten fresh) 0.01 ~ 0.03% by weight, xylitol 0.1 ~ 0.5% by weight and the balance can be included.
더욱 바람직하게는 상기의 기능성 음료조성물은 음료조성물 전체중량 대비, 선인장 추출물 5중량%, 액상과당 15중량%, 벌꿀 0.7중량%, 로얄제리추출물 0.7중량%, 구연산 0.1중량%, 젖산칼슘 0.1중량%, 비타민 C 0.03중량%, 향료(스테비텐후레쉬) 0.02중량%, 자일리톨 0.3중량% 및 잔부의 정제수를 포함할 수 있다.More preferably, the functional beverage composition is based on the total weight of the beverage composition,
본 발명은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장으로부터 선인장 추출물을 추출하는 단계를 포함하는 것을 특징으로 하는 비독성, 항산화 및 항비만 활성을 가지는 건강식품조성물의 제조방법을 제공한다.The present invention provides a method for producing a health food composition having a non-toxic, antioxidant and anti-obesity activity, comprising extracting a cactus extract from any one cactus selected from the group consisting of bogeum, daegyeong and kumho. .
본 발명에서 상기의 제조방법은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장을 세척 및 절단하여 준비하는 단계;와 상기 준비된 선인장에 정제수 또는 알코올 중에서 선택된 어느 하나 이상의 용매를 선인장 부피의 8~12배로 가하고, 6~10시간 동안 80~100℃에서 추출하여 선인장 추출물을 얻는 단계; 및 상기 선인장 추출물을 60~80 Brix 로 농축시켜 선인장 농축액을 얻는 단계;를 포함할 수 있다.In the present invention, the preparation method comprises the steps of preparing and washing and cutting any one cactus selected from the group consisting of bogeum, large diameter and Kumho; and at least one solvent selected from purified water or alcohol to the prepared cactus Adding to 12-fold, extracting at 80-100 ° C. for 6-10 hours to obtain a cactus extract; And concentrating the cactus extract to 60 to 80 Brix to obtain a cactus concentrate.
바람직하게는 상기의 제조방법은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장을 세척 및 절단하여 준비하는 단계;와 상기 준비된 선인장에 정제수 및 알코올을 95:5의 비율로 혼합한 용매를 선인장 부피의 10배로 가하고 8시간 동안 90℃에서 추출하여 선인장 추출물을 얻는 단계; 및 상기 선인장 추출물을 70 Brix 로 농축시켜 선인장 농축액을 얻는 단계;를 포함할 수 있다. Preferably, the preparation method comprises the steps of preparing and washing and cutting any one cactus selected from the group consisting of bogeum, Daekyung and Kumho; and a solvent in which purified water and alcohol are mixed in a ratio of 95: 5 to the prepared cactus. Adding 10 times the cactus volume and extracting at 90 ° C. for 8 hours to obtain a cactus extract; And concentrating the cactus extract to 70 Brix to obtain a cactus concentrate.
이러한 추출 및 농축조건이 선인장 추출물의 추출수율을 높이며, 상온에서 12개월 이상 보존이 가능토록 하기 때문이다. 또한 상기의 용매추출법 이외에도 공지의 추출법을 이용하여 선인장 추출물을 제조할 수 있다.This is because the extraction and concentration conditions increase the extraction yield of the cactus extract, so that it can be preserved for more than 12 months at room temperature. In addition to the solvent extraction method, it is possible to produce a cactus extract using a known extraction method.
또한 본 발명은 상기의 방법으로 제조된 선인장 추출물을 첨가하는 단계를 포함하는 것을 특징으로 하는 기능성 음료조성물의 제조방법을 제공한다.The present invention also provides a method for producing a functional beverage composition comprising the step of adding a cactus extract prepared by the above method.
본 발명에서 상기 기능성 음료조성물의 제조방법은 보검, 대경 및 금호로 이루어진 군에서 선택된 어느 하나의 선인장으로부터 선인장 추출물을 추출하는 단계;와 상기 선인장 추출물에 액상과당, 벌꿀, 로얄제리추출물, 구연산, 젖산칼슘, 비타민 C, 향료(스테비텐후레쉬), 자일리톨 및 정제수를 더 첨가하는 단계;를 포함할 수 있다.Method for producing the functional beverage composition in the present invention comprises the steps of extracting the cactus extract from any one cactus selected from the group consisting of bogeum, Daegyeong and Kumho; and liquid fructose, honey, royal jelly extract, citric acid, lactic acid in the cactus extract It may include; adding calcium, vitamin C, flavoring (stevitene fresh), xylitol and purified water.
바람직하게는 상기 기능성 음료조성물의 제조방법은 음료조성물 전체중량 대비, 선인장 추출물 1~10중량%, 액상과당 10~20중량%, 벌꿀 0.5~1.0중량%, 로얄제리추출물 0.5~1.0중량%, 구연산 0.05~0.15중량%, 젖산칼슘 0.05~0.15중량%, 비타민 C 0.01~0.05중량%, 향료(스테비텐후레쉬) 0.01~0.03중량%, 자일리톨 0.1~0.5중량% 및 잔부의 정제수를 첨가할 수 있다.Preferably, the method for preparing the functional beverage composition is based on the total weight of the beverage composition, cactus extract 1-10% by weight, liquid fructose 10-20% by weight, honey 0.5-1.0% by weight, royal jelly extract 0.5-1.0% by weight, citric acid 0.05% to 0.15% by weight, 0.05% to 0.15% by weight of calcium lactate, 0.01% to 0.05% by weight of vitamin C, 0.01% to 0.03% by weight of fragrance (stevitene fresh), 0.1% to 0.5% by weight of xylitol, and the remaining purified water can be added.
더욱 바람직하게는 상기의 기능성 음료조성물의 제조방법은 음료조성물 전체중량 대비, 선인장 추출물 5중량%, 액상과당 15중량%, 벌꿀 0.7중량%, 로얄제리추출물 0.7중량%, 구연산 0.1중량%, 젖산칼슘 0.1중량%, 비타민 C 0.03중량%, 향료(스테비텐후레쉬) 0.02중량%, 자일리톨 0.3중량% 및 잔부의 정제수를 첨가할 수 있다.More preferably, the method for preparing the functional beverage composition is based on the total weight of the beverage composition,
이하 본 발명의 실시예 및 실험예를 살핀다. 이하의 실시예 및 실험예는 본 발명을 더욱 상세하게 설명하기 위한 것으로, 본 발명의 권리범위를 이에 한정하고자 하는 것은 아니다. Hereinafter, the Examples and Experimental Examples of the present invention. The following Examples and Experimental Examples are intended to explain the present invention in more detail, and the scope of the present invention is not intended to be limited thereto.
<실시예 1> 보검 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 조성물의 제조Example 1 Preparation of a Composition Having Non-Toxic, Antioxidant and Anti-obesity Activity Containing Bochum Extract
1. 선인장인 보검은 고양시에서 대량 재배되고 있으며, 이를 본 발명의 실시를 위하여 사용하였다.1. The cactus bogeum is cultivated in Goyang-si and used for the practice of the present invention.
2. 상기 보검 1㎏을 물로 깨끗이 세척하고, 세척된 보검을 절단한다. 2. Wash the 1kg of the boil with water and cut the washed bogeum.
3. 절단된 보검에 정제수 19ℓ와 에탄올 1ℓ의 혼합용매를 첨가하여 8시간 동안 90℃에서 용매추출시켰다. 상등액을 원심분리하여 보검 추출물을 얻었다.3. The solvent was extracted at 90 ° C. for 8 hours by adding a mixed solvent of purified water 19 L and ethanol 1 L to the cut test. The supernatant was centrifuged to obtain a bogeum extract.
4. 상기 보검 추출물에 더욱 열을 가하여 보검 추출물이 70 Brix 까지 되도록 농축시켰다.4. The bogeum extract was further heated to concentrate the bogeum extract to 70 Brix.
<실시예 2> 대경 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 조성물의 제조Example 2 Preparation of a Composition Having Non-Toxic, Antioxidant and Anti-obesity Activity Containing Large Diameter Extract
1. 선인장인 대검은 고양시에서 대량 재배되고 있으며, 이를 본 발명의 실시를 위하여 사용하였다.1. A cactus bayonet is cultivated in Goyang-si and used for the practice of the present invention.
2. 상기 대경 1㎏을 물로 깨끗이 세척하고, 세척된 대경을 절단한다. 2. Wash the
3. 절단된 대경에 정제수 19ℓ와 에탄올 1ℓ의 혼합용매를 첨가하여 8시간 동안 90℃에서 용매추출시켰다. 상등액을 원심분리하여 대경 추출물을 얻었다.3. A mixed solvent of purified water 19 L and ethanol 1 L was added to the cut large diameter, and the solvent was extracted at 90 ° C. for 8 hours. The supernatant was centrifuged to obtain a large diameter extract.
4. 상기 대경 추출물에 더욱 열을 가하여 대경 추출물이 70 Brix 까지 되도록 농축시켰다.4. The large diameter extract was further heated to concentrate the large diameter extract to 70 Brix.
<실시예 3> 금호 추출물을 함유하는 비독성, 항산화 및 항비만 활성을 가지는 조성물의 제조Example 3 Preparation of a Composition Having Non-Toxic, Antioxidant and Anti-obesity Activity Containing Kumho Extract
1. 선인장인 금호는 고양시에서 대량 재배되고 있으며, 이를 본 발명의 실시를 위하여 사용하였다.1. Kumho, which is a cactus, is cultivated in Goyang-si and used for the practice of the present invention.
2. 상기 금호 1㎏을 물로 깨끗이 세척하고, 세척된 금호를 절단한다. 2.
3. 절단된 금호에 정제수 19ℓ와 에탄올 1ℓ의 혼합용매를 첨가하여 8시간 동안 90℃에서 용매추출시켰다. 상등액을 원심분리하여 금호 추출물을 얻었다.3. The solvent was extracted at 90 ° C. for 8 hours by adding a mixed solvent of purified water 19 L and ethanol 1 L to the cut Kumho. The supernatant was centrifuged to obtain a Kumho extract.
4. 상기 금호 추출물에 더욱 열을 가하여 금호 추출물이 70 Brix 까지 되도록 농축시켰다.4. The Kumho extract was further heated to concentrate the Kumho extract to 70 Brix.
<실시예 4-11> 보검 추출물을 첨가한 기능성 음료조성물의 제조Example 4-11 Preparation of Functional Beverage Composition Added Bogeum Extract
1. 상기 실시예 1에서 얻어진 보검 추출물을 이용하여 음료조성물을 제조하였다. 또한 첨가되는 첨가물들은 공지의 시판되는 물질들로 시중의 마트나 첨가물 상가에서 구입하였다.1. A beverage composition was prepared using the bogeum extract obtained in Example 1. Additives to be added were also purchased from commercial marts or additive stores with known commercially available materials.
2. 실시예 4는, 보검으로부터 보검 추출물을 얻고, 상기 보검 추출물 5㎖에 액상과당 15㎖, 벌꿀 0.7㎖, 로얄제리추출물 0.7㎖, 구연산 0.1㎎, 젖산칼슘 0.1㎎, 비타민 C 0.03㎎, 향료(스테비텐후레쉬) 0.02㎎, 자일리톨 0.3㎖ 및 정제수 78.05㎖를 첨가하여 음료를 제조한 것이다. 2. In Example 4, a bogeum extract was obtained from a bogeum, and 15 mL of liquid fructose, 0.7 mL of honey, 0.7 mL of royal jelly extract, 0.1 mL of citric acid, 0.1 mg of calcium lactate, and 0.03 mg of vitamin C were added to 5 mL of the bogeum extract. (Stebiten fresh) 0.02 mg, 0.3 ml of xylitol and 78.05 ml of purified water were added to prepare a beverage.
3. 상기 실시예 4와 같은 방법으로 음료를 제조하되, 보검 추출물의 함량과 정제수의 함량만을 달리하여 음료를 제조하였다(실시예 5-8)(이하 표 1 참조).3. A beverage was prepared in the same manner as in Example 4, except that only the content of bogeum extract and the content of purified water were prepared (Example 5-8) (see Table 1 below).
4. 또한 상기 실시예 4와 같은 방법으로 음료를 제조하되, 액상과당의 함량과 정제수의 함량만을 달리하여 음료를 제조하였다(실시예 9-11)(이하 표 2 참조).4. Also, a beverage was prepared in the same manner as in Example 4, except that only the content of liquid fructose and the content of purified water were prepared (Example 9-11) (see Table 2 below).
[표 1] 보검 추출물의 함량을 달리한 음료제조(단위:㎖)[Table 1] Preparation of beverages with different content of bogeum extract (unit: ml)
The remaining ingredient content is the same as in Example 4
[표 2] 액상과당의 함량을 달리한 음료제조(단위:㎖)[Table 2] Production of beverages with different content of liquid fructose (unit: ml)
<실시예 12-19> 대경 추출물을 첨가한 기능성 음료조성물의 제조<Example 12-19> Preparation of the functional beverage composition to which the large diameter extract is added
1. 상기 실시예 2에서 얻어진 대경 추출물을 이용하여 음료조성물을 제조하였다. 또한 첨가되는 첨가물들은 공지의 시판되는 물질들로 시중의 마트나 첨가물 상가에서 구입하였다.1. Using the large diameter extract obtained in Example 2 to prepare a beverage composition. Additives to be added were also purchased from commercial marts or additive stores with known commercially available materials.
2. 실시예 12는, 대경으로부터 대경 추출물을 얻고, 상기 대경 추출물 5㎖에 액상과당 15㎖, 벌꿀 0.7㎖, 로얄제리추출물 0.7㎖, 구연산 0.1㎎, 젖산칼슘 0.1㎎, 비타민 C 0.03㎎, 향료(스테비텐후레쉬) 0.02㎎, 자일리톨 0.3㎖ 및 정제수 78.05㎖를 첨가하여 음료를 제조한 것이다. 2. In Example 12, a large diameter extract was obtained from a large diameter, and 5 ml of the large diameter extract was 15 ml of liquid fructose, 0.7 ml of honey, 0.7 ml of royal jelly extract, 0.1 mg of citric acid, 0.1 mg of calcium lactate, and 0.03 mg of vitamin C. (Stebiten fresh) 0.02 mg, 0.3 ml of xylitol and 78.05 ml of purified water were added to prepare a beverage.
3. 상기 실시예 12와 같은 방법으로 음료를 제조하되, 대경 추출물의 함량과 정제수의 함량만을 달리하여 음료를 제조하였다(실시예 13-16)(이하 표 3 참조).3. A beverage was prepared in the same manner as in Example 12, except that only the content of the large diameter extract and the content of purified water were prepared (Example 13-16) (see Table 3 below).
4. 또한 상기 실시예 12와 같은 방법으로 음료를 제조하되, 액상과당의 함량과 정제수의 함량만을 달리하여 음료를 제조하였다(실시예 17-19)(이하 표 4 참조).4. In addition, a beverage was prepared in the same manner as in Example 12, except that only the content of liquid fructose and the content of purified water were prepared (Examples 17-19) (see Table 4 below).
[표 3] 대경 추출물의 함량을 달리한 음료제조(단위:㎖)[Table 3] Production of beverages with different contents of large diameter extract (unit: ml)
The remaining ingredient content is the same as in Example 12
[표 4] 액상과당의 함량을 달리한 음료제조(단위:㎖)[Table 4] Production of beverages with different content of liquid fructose (unit: ml)
<실시예 20-27> 금호 추출물을 첨가한 기능성 음료조성물의 제조Example 20-27 Preparation of a Functional Beverage Composition Added Kumho Extract
1. 상기 실시예 3에서 얻어진 금호 추출물을 이용하여 음료조성물을 제조하였다. 또한 첨가되는 첨가물들은 공지의 시판되는 물질들로 시중의 마트나 첨가물 상가에서 구입하였다.1. A beverage composition was prepared using the Kumho extract obtained in Example 3. Additives to be added were also purchased from commercial marts or additive stores with known commercially available materials.
2. 실시예 20은, 금호로부터 금호 추출물을 얻고, 상기 금호 추출물 5㎖에 액상과당 15㎖, 벌꿀 0.7㎖, 로얄제리추출물 0.7㎖, 구연산 0.1㎎, 젖산칼슘 0.1㎎, 비타민 C 0.03㎎, 향료(스테비텐후레쉬) 0.02㎎, 자일리톨 0.3㎖ 및 정제수 78.05㎖를 첨가하여 음료를 제조한 것이다. 2. In Example 20, a Kumho extract was obtained from Kumho, and 5 ml of the Kumho extract was added 15 ml of liquid fructose, 0.7 ml of honey, 0.7 ml of royal jelly extract, 0.1 mg of citric acid, 0.1 mg of calcium lactate, and 0.03 mg of vitamin C. (Stebiten fresh) 0.02 mg, 0.3 ml of xylitol and 78.05 ml of purified water were added to prepare a beverage.
3. 상기 실시예 20와 같은 방법으로 음료를 제조하되, 금호 추출물의 함량과 정제수의 함량만을 달리하여 음료를 제조하였다(실시예 21-24)(이하 표 5 참조).3. A beverage was prepared in the same manner as in Example 20, except that only the content of Kumho extract and the content of purified water were prepared (Examples 21-24) (see Table 5 below).
4. 또한 상기 실시예 20와 같은 방법으로 음료를 제조하되, 액상과당의 함량과 정제수의 함량만을 달리하여 음료를 제조하였다(실시예 25-27)(이하 표 6 참조).4. Also, a beverage was prepared in the same manner as in Example 20, except that only the content of liquid fructose and the content of purified water were prepared (Examples 25-27) (see Table 6 below).
[표 5] 금호 추출물의 함량을 달리한 음료제조(단위:㎖)[Table 5] Production of beverages with different content of Kumho extract (unit: ml)
The remaining ingredient content is the same as in Example 20
[표 6] 액상과당의 함량을 달리한 음료제조(단위:㎖)[Table 6] Production of beverages with different content of liquid fructose (unit: ml)
<실험예 1>Experimental Example 1
상기 살핀 실시예 1-3 에 의하여 제조된 선인장 추출물을 이용하여 1) 세포사멸에 의한 독성확인 실험, 2) 변이원성 및 항변이원성 실험, 3) 전체 폴리페놀(Total polyphenol) 함량 측정 실험, 4) 전자공여작용(DPPH) 측정 실험, 5) 판크레아틱 리파아제(Pancreatic lipase) 활성 저해물질의 탐색 및 저해능 측정, 6) 피부 재생력 및 항염증 활성 실험 및 7) 항 당뇨 및 혈전용해 활성 실험을 하였다.1) Toxicity Confirmation Test by Apoptosis, 2) Mutagenicity and Antimutagenicity Test, 3) Total Polyphenol Content Measurement Test, 4) Electronic A donation (DPPH) measurement experiment, 5) pancreatic lipase activity inhibitors and inhibitory activity measurement, 6) skin regeneration and anti-inflammatory activity test and 7) anti-diabetic and thrombolytic activity test.
1. 세포사멸에 의한 독성확인 실험1. Toxicity test by cell death
(1) 실시예 1-3 에 의하여 제조된 추출물(시료)을 얻고, 각각의 추출물을 100ug/ml의 단위로 DMSO에 재용해하고, 이용액 10ul를 30mm의 plate에서 증식하는 골암세포(osteoblastoma) U2OS에 처리를 하였다. 이 때 배양액은 10% fetal bovine serum (Hyclone, Logan, UT)을 포함하는 Dulbecco’s modified Eagle’s Medium에 1% 페니실린/스트렙토마이신(penicillin/streptomycin) (Invitrogen, UK)를 처리하 여 사용하였으며 대조군으로 etoposide 20 uM과 DMSO만을 처리하였다. 각 시료를 처리한 24시간 후 세포들을 광학현미경을 이용하여 세포의 증식 상태를 관찰하였으며 세포의 상태에 따라 각 시료의 독성도를 비독성[no effect(-)], 약한 독성[mildly toxic(+)], 독성[toxic(++)], 강한 독성[very toxic(+++)]으로 구분하였다. 상기 세포사멸에 의한 세포독성의 결과는 이하의 표 7와 같았다.(1) Obtained extracts (samples) prepared in Examples 1-3, each extract was re-dissolved in DMSO in units of 100ug / ml, and 10ul of the solution was used to proliferate in a 30mm plate of osteoblastoma U2OS Was treated. At this time, the culture medium was treated with 1% penicillin / streptomycin (Invitrogen, UK) in Dulbecco's modified Eagle's Medium containing 10% fetal bovine serum (Hyclone, Logan, UT) and
[표 7] 세포독성 결과 1TABLE 7
보검
Bog
대경
Daekyung
금호
Kumho
(2) 또한 미식용 선인장 중에서 세포독성이 강하여 항암제로서만 사용 가능성이 있는 선인장들의 세포독성 실험도 비교대상으로 하였다(이하 표 8 참조).(2) In addition, the cytotoxicity test of cactus, which is likely to be used only as an anticancer agent due to its high cytotoxicity among gourmet cactus, was also compared (see Table 8 below).
[표 8] 세포독성 결과 2TABLE 8
(3) 상기 표 7 및 8에서 알 수 있듯이, 세포주를 이용한 안정성 시험결과 보검, 대경, 금호 모두 안전한 것으로 나타났다. 비교대상인 화제, 염좌, 일월금, 흑법사, 불사조, 부용, 청솔 등은 1ug/uL에서도 강한 세포독성을 보여 식용으로는 불가능하나, 차후 항암제로서의 개발 가능성을 나타내었다. (3) As can be seen in Tables 7 and 8, the stability test results using the cell line showed that all of the test, Daekyung, and Kumho were safe. Comparative topics, sprains, ilwolum, black sorcerers, phoenix, bouillon, blue sol, etc. showed strong cytotoxicity even at 1ug / uL, which was impossible for food use, but showed potential for future development as anticancer agent.
2. 변이원성 및 항변이원성 실험2. Mutagenicity and Antimutagenicity
(1) 미생물 복귀 돌연변이 실험(1) microbial return mutation experiment
1) Maron과 Ames(1983)의 방법에 따라 살모넬라 티피무리움(Salmonella typhimurium) TA98 및 살모넬라 티피무리움 TA100을 이용하여 자연 복귀돌연 변이수에 대한 각 시료(선인장 추출물:실시예 1-3 및 비교대상으로 당인, 화제 추출물 포함) 처리 후의 자연 복귀돌연 변이수를 측정하여 변이수가 2배 이상 증가하였을 경우 변이원성이 있는 것으로 판단하였다. 항변이원성의 경우 돌연변이원으로 acetamidofluorene 및 benzo(a)pyrene, nitrofluorene을 사용하여 각 선인장 추출물의 항 돌연변이성을 알아보기 위하여 멸균된 microtube에 시료 5.0㎍ 씩 넣은 후 S9 mix(간접변이원) 500㎕ 혹은 phosphate buffer(직접변이원) 500㎕, 균주 100㎕, 돌연변이원 100㎕를 차례로 넣고 37℃ water bath에서 30분간 전 배양하였다. 이것을 46℃의 top agar 2㎖에 첨가한 후 최소평판배지(minimal glucose agar plates)에 overlay 하고, 37℃ incubator에서 48시간 동안 배양 후 plate 상의 revertant colony 수를 개수하였다.1) Each sample (cactus extract: Examples 1-3 and comparison with natural return mutations) using Salmonella typhimurium TA98 and Salmonella typhimurium TA100 according to the method of Maron and Ames (1983) The subjects were determined to have mutagenicity when the number of mutations increased by more than two times by measuring the natural number of mutations after treatment with sugar, topical extracts). For antimutagenicity, acetamidofluorene, benzo (a) pyrene, and nitrofluorene were used as mutagens. In order to determine the antimutagenicity of each cactus extract, 5.0 µl of sample was added to a sterile microtube and 500 µl of S9 mix (indirect mutagen). 500 μl of phosphate buffer (direct mutant), 100 μl of strain, and 100 μl of mutant were added sequentially and incubated for 30 minutes in a 37 ° C. water bath. This was added to 2 ml of top agar at 46 ° C. and then overlayed onto minimal glucose agar plates, and cultured in a 37 ° C. incubator for 48 hours, and the number of revertant colonies on the plate was counted.
2) 살모넬라 티피무리움 TA98 및 살모넬라 티피무리움 TA100을 이용하여 돌연변이 발생 실험을 한 결과는 도 1과 같았다. 즉 살모넬라 티피무리움 TA100의 경우 선인장을 처리하지 않은 대조군의 경우 복귀 돌연변이 수가 417개로 나타났으며 시료 처리시 금호 366, 당인 480, 화제 500, 대경 487, 보검 394개로 대조군의 복귀 돌연변이수 보다 2배 이상 증가하지 않아 돌연변이를 일으킬 위험성이 없는 것으로 나타났다. 또한 살모넬라 티피무리움 TA98의 경우 대조군의 복귀 돌연변이 수는 111개로 시료 처리시 금호 95, 당인 93, 화제 89, 대경 94, 보검 89개로 대조군의 복귀 돌연변이수 보다 2배 이상 증가하지 않아 돌연변이를 일으킬 위험성이 없는 것으로 나타났다. 따라서 본 실험에 사용한 선인장의 경우 돌연변이 위험성은 없는 것으로 밝혀졌다(도 1 참조). 2) The results of mutation experiments using Salmonella typhimurium TA98 and Salmonella typhimurium TA100 were as shown in FIG. 1. In the Salmonella typhimurium TA100, the control group without cactus showed 417 return mutations, and the sample was treated with Kumho 366, sugar 480, topic 500, large diameter 487, and 394 gums, which was twice the number of return mutations in the control group. It did not increase abnormally, indicating that there is no risk of mutation. In the case of Salmonella typhimurium TA98, the number of return mutations in the control group was 111, and the risk of causing mutations was not increased by more than twice the number of return mutations in the control group when the sample was processed, Kumho 95, Glucose 93, Topical 89, Large diameter 94, and Bogeum 89. Appeared to be missing. Therefore, it was found that the cactus used in this experiment was not at risk of mutation (see FIG. 1).
(2) 항 돌연변이활성 시험 (2) anti mutagenicity test
1) Maron과 Ames(1983)의 방법에 따라 살모넬라 티피무리움(Salmonella typhimurium) TA98 및 살모넬라 티피무리움 TA100을 이용하여 돌연변이원을 사용한 후 각 선인장 시료의 항 돌연변이활성을 확인한 결과는 이하의 표 9 및 10과 같았다. 1) According to the method of Maron and Ames (1983), after using the mutagen using Salmonella typhimurium TA98 and Salmonella typhimurium TA100, the results of confirming the anti-mutant activity of each cactus sample are shown in Table 9 below. And 10.
[표 9] 살모넬라 티피무리움(Salmonella typhimurium) TA100에 대한 선인장 추출물의 항 돌연변이 활성 Table 9 Antimutagenic Activity of Cactus Extracts against Salmonella typhimurium TA100
[표 10] 살모넬라 티피무리움(Salmonella typhimurium) TA98에 대한 선인장 추출물의 항 돌연변이 활성 Table 10 Antimutagenic Activities of Cactus Extracts against Salmonella typhimurium TA98
2) 상기 표 9에서 알 수 있듯이 살모넬라 티피무리움 TA100에 돌연변이원으로 acetamidofluorene 및 benzo(a)pyrene, nitrofluorene을 처리한 경우 복귀 돌연변이 수가 대조군인 269에서 365, 313, 352로 증가하였으며 선인장 추출물을 처리했을 경우 acetamidofluorene의 경우 화제가 항 돌연변이 활성을 나타내었고, benzopyrene의 경우 보검 추출물이 항 돌연변이 활성을 그리고 nitrofluorene에 대해서는 항돌연변이 활성이 없는 것으로 나타났다. 2) As can be seen from Table 9, when acetamidofluorene, benzo (a) pyrene, and nitrofluorene were treated as a mutagen in Salmonella typhimurium TA100, the number of return mutations was increased from 269 as a control to 365, 313, and 352. In the case of acetamidofluorene, the topicality showed antimutagenic activity, and in the case of benzopyrene, bogeum extract showed antimutagenic activity and no antimutagenic activity for nitrofluorene.
상기 표 10에서 알 수 있듯이 살모넬라 티피무리움 TA98의 경우는 돌연변이원으로 acetamidofluorene 및 benzo(a)pyrene, nitrofluorene을 처리한 경우 복귀 돌연변이 수가 대조군인 268에서 324, 341, 365로 증가하였으며 선인장 추출물을 처리했을 경우 acetamidofluorene의 경우 당인 및 화제, 대경이 항 돌연변이 활성을 나타냈으며, benzopyrene의 경우 보검 추출물이 약간의 항 돌연변이 활성을 그 리고 nitrofluorene에 대해서는 항 돌연변이 활성이 거의 없는 것으로 나타났다.As can be seen in Table 10, in the case of Salmonella typhimurium TA98, when the acetamidofluorene, benzo (a) pyrene, and nitrofluorene were treated as mutagens, the number of return mutations increased from 268 to 324, 341, and 365, and the cactus extract was treated. In the case of acetamidofluorene, sugar, topical and large diameter showed anti-mutant activity, and in the case of benzopyrene, boge extract showed slight anti-mutant activity and little anti-mutant activity for nitrofluorene.
3. 전체 폴리페놀 함량 측정 실험3. Total Polyphenol Content Measurement Experiment
(1) 항산화물질로 대표되는 폴리페놀(polyphenol) 함량의 측정은 Folin-densis법(Slinkard 등,1974)을 변형하여 측정하였다. 즉, 각 시료(실시예 1-3 및 화제의 추출물)(1㎎/㎖) 0.5㎖를 tube에 넣고 증류수 6.5㎖를 가한 후, 0.5㎖의 folin-ciocalteu's phenol용액을 넣고 25℃에서 3분간 반응시켰다. 그리고 sodium bicarbonate 포화용액 1㎖와 증류수 1.5㎖를 차례로 첨가한 후 25℃에서 1시간 동안 반응시킨 후 750nm에서 흡광도를 측정하였으며 총 폴리페놀 화합물을 정량하기 위한 표준곡선은 galic acid를 사용하여 작성하였다. (1) The polyphenol content, which is represented by antioxidants, was measured by modifying the Folin-densis method (Slinkard et al., 1974). That is, 0.5 ml of each sample (Example 1-3 and a topical extract) (1 mg / ml) was added to a tube, and 6.5 ml of distilled water was added. Then, 0.5 ml of folin-ciocalteu's phenol solution was added and reacted at 25 ° C. for 3 minutes. I was. In addition, 1 ml of saturated sodium bicarbonate solution and 1.5 ml of distilled water were added sequentially, and then reacted at 25 ° C. for 1 hour, and the absorbance was measured at 750 nm. The standard curve for quantifying total polyphenolic compounds was prepared using galic acid.
(2) 총 폴리페놀함량을 측정한 결과 금호 7.75mg%, 대경 1.16mg%, 보검 5.20mg%, 화제 15.56mg% 로 측정되었다. (2) As a result of measuring the total polyphenol content, it was measured as Kumho 7.75mg%, large diameter 1.16mg%, bogeum 5.20mg%, topic 15.56mg%.
4. 전자공여작용 측정 실험4. Electron Donation Measurement Experiment
(1) 항산화력을 측정하는 방법으로 전자를 제공함으로써 프리 라디컬(free radical)을 제거하여 산화과정을 정지시키는 전자공여작용(electron donating abilities)은 Mensor 등(2001)의 방법을 변형하여 각 선인장 추출물(실시예 1-3 및 화제와 비교대상으로 비타민 C, BHT)에 대한 DPPH(α,α-diphenyl-picrylhydrazyl)의 전자공여효과로 각 시료의 환원력을 측정하였다. 즉, 0.3mM DPPH 용액 1㎖에 각 시료 2.5㎖를 혼합하고 이 반응액을 약 10초간 혼합하고 실온에 10분간 반응한 후 분광광도계를 사용하여 525nm에서 흡광도를 측정하였다.(1) The electron donating abilities that stop the oxidation process by removing free radicals by providing electrons as a method of measuring antioxidant power are modified by the method of Mensor et al. (2001). The reducing power of each sample was measured by the electron donating effect of DPPH (α, α-diphenyl-picrylhydrazyl) on extracts (Examples 1-3 and vitamin C, BHT compared to the topic). That is, 2.5 ml of each sample was mixed with 1 ml of 0.3 mM DPPH solution, the reaction solution was mixed for about 10 seconds, and reacted at room temperature for 10 minutes, and then absorbance was measured at 525 nm using a spectrophotometer.
(2) 금호, 대경, 보검, 화제 4종에 대해 1㎎/㎖ 농도로 DPPH를 측정한 결과는 도 2와 같았으며 대조군으로 항산화 작용이 있는 비타민 C와 합성 항산화제인 BHT를 사용하였다. 즉 Vitamin C 및 BHT에 비해 화제의 경우 약 70-80% 정도의 전자공여활성을 나타냈으며 보검 및 대경의 경우 약 30-40% 수준을 보여주었다. 따라서 비타민 C 나 BHT 정도는 아니라도 어느 정도의 항산화 효과를 가지는 기능성 추출물로서 증명되었다고 할 수 있었다.(도 2 참조). (2) DPPH was measured at the concentration of 1 mg / ml for Kumho, Daekyung, Bogum, and Topicals as shown in FIG. 2, and vitamin C having antioxidant activity and BHT as a synthetic antioxidant were used as a control. That is, compared with Vitamin C and BHT, it showed about 70-80% of electron donating activity in topic, and about 30-40% in bogeum and large diameter. Therefore, it could be said that it was proved as a functional extract having some degree of antioxidant effect even if not vitamin C or BHT (see Fig. 2).
5. 판크레아틱 리파아제 활성 저해물질의 탐색 및 저해능 측정 실험5. Screening and Inhibition of Pancreatic Lipase Activity Inhibitors
(1) 판크레아틱 리파아제(Pancreatic lipase)의 활성을 억제하게 되면 섭취된 지방의 체내 흡수를 방해하여 체외로 배출시키기 때문에 지방의 과다 섭취에 따른 비만을 예방할 수 있다. (1) Inhibiting the activity of pancreatic lipase (Pancreatic lipase) to prevent the fat absorption of the ingested fat in the body because it can be prevented from obesity due to excessive intake of fat.
실시예 1-3 및 비교대상선인장들에 의하여 제조된 각 시료를 농도 1 mg/ml이 되도록 제조한 후, 판크레아틱 리파아제 용액과 섞어 3분간 반응시키고 트리부틸린(tributylin)을 함유한 평판배지의 paper disk에 분주한 다음 4시간 후 투명환(clear zone)의 크기를 측정하여 환의 크기가 작은 시료를 1차 탐색하여 판크레아틱 리파아제의 활성을 억제하는 선인장 시료를 선정하였다. 이렇게 선정된 시료를 사용하여 판크레아틱 리파아제활성 저해능 측정을 하였고, 그 방법으로 Bitou 등의 방법에 따라 트리올레인(triolein)으로부터 분리되는 올레인산(oleic acid)량을 측정하였다. Each sample prepared by Example 1-3 and the comparative cactus was prepared to have a concentration of 1 mg / ml, and then mixed with a pancreatic lipase solution and reacted for 3 minutes, and the plate medium containing tributyllin (tributylin). Four hours after dispensing on the paper disk of the clear zone (clear zone) by measuring the size of the clear ring (small zone) samples were first searched for cactus samples that inhibit the activity of pancreatic lipase was selected. The selected sample was used to measure pancreatic lipase activity inhibition activity, and the amount of oleic acid separated from triolein was measured according to the method of Bitou et al.
즉, 기질은 0.1M NaCl이 첨가된 0.1M N-tris (hydroxymethyl)methyl-2-aminoethanesulfonic acid(pH 7.0) 9 ml에 90 μmol triolein, 45 ㎎ gum arabic과 9.45 μmol taurocholic acid을 넣고 초음파로 5분 동안 처리하여 제조하였다. 리파아제 활성측정을 위한 반응용액은 효소용액(pancreatic lipase, 1500 U/ml) 15 ㎕, 식물추출물 5 ㎕, 기질용액 180 ㎕을 섞어 최종 반응용액의 부피는 200 ㎕ 되도록 제조한 후, pH 7.0, 반응온도 37℃에서 30분간 반응시켰다. In other words, the substrate was prepared by adding 90 μmol triolein, 45 mg gum arabic and 9.45 μmol taurocholic acid to 9 ml of 0.1 M N-tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid (pH 7.0) added with 0.1 M NaCl for 5 minutes by ultrasonic wave. Prepared by treatment. The reaction solution for measuring lipase activity was prepared by mixing 15 μl of enzyme solution (pancreatic lipase (1500 U / ml), 5 μl of plant extract, 180 μl of substrate solution) so that the volume of the final reaction solution was 200 μl, and then pH 7.0, reaction. It reacted at the temperature of 37 degreeC for 30 minutes.
효소반응 후 생성된 올레인산 정량은 Zapf 등의 방법에 따라 효소반응 후 반응액 0.2 ml에 2%(v/v) 메탄올(methanol)이 포함된 클로로-포/헵탄(chloro-form/heptane)(1:1) 용액3 ml을 첨가하여 10분 동안 교반한 후, 10분간 원심분리(2,000× g)하여 수층을 제거하였다. 여기에 구리(copper) 반응액 1 ml을 첨가하여 다시 10분 동안 교반한 후, 10분 동안 원심분리(2,000×g)하여 추출된 올레인산과 구리염(copper salt)가 포함된 유기용매 층 1 ml을 취하여 0.05%(w/v) 3-tert-butyl-4-hydroxyanisole이 포함된 0.1%(w/v) batho- cuprione 용액 1 ml을 첨가한 후, 480 nm에서 흡광도를 측정하여 올레인산을 정량함으로써 효소 활성을 측정하였다.Determination of oleic acid produced after enzymatic reaction was carried out by chloro-form / heptane containing 2% (v / v) methanol in 0.2 ml of the reaction solution after the enzymatic reaction according to the method of Zapf et al. : 1) 3 ml of solution was added and stirred for 10 minutes, followed by centrifugation (2,000 × g) for 10 minutes to remove the aqueous layer. 1 ml of copper reaction solution was added thereto and stirred for another 10 minutes, followed by centrifugation (2,000 × g) for 10 minutes, and 1 ml of an organic solvent layer containing oleic acid and copper salt extracted. 1 ml of 0.1% (w / v) batho-cuprione solution containing 0.05% (w / v) 3-tert-butyl-4-hydroxyanisole was added, and the absorbance was measured at 480 nm to quantify oleic acid. Enzyme activity was measured.
(2) 어느 섭취된 지방이 장관 벽을 통하여 체내로 흡수되기 위해서 필수적으로 중성지방인 트리-글리세리드(tri-glyceride)가 지방산과 글리세롤(glycerol)로 분해되어야 한다. 췌장에서 분비되는 판크레아틱 리파아제의 작용은 트리-글리세리드를 지방산과 글리세롤로 분해하여 음식으로 섭취된 지방이 체내로 흡수되도록 작용한다. 따라서 판크레아틱 리파아제의 활성을 억제하게 되면 섭취된 지방의 체내흡수를 방해하여 체외로 배출시키기 때문에 지방의 과다 섭취에 따른 비만을 예방할 수 있는 것으로 알려져 있다. (2) Triglycerides, which are essentially triglycerides, must be broken down into fatty acids and glycerol in order for any ingested fat to be absorbed into the body through the intestinal wall. The action of pancreatic lipases secreted by the pancreas breaks down tri-glycerides into fatty acids and glycerol, so that the fats taken from food are absorbed into the body. Therefore, inhibiting the activity of pancreatic lipase is known to prevent obesity due to excessive intake of fat because it inhibits the body's absorption of ingested fat into the body.
본 실험에서는 고양시에서 대량 재배되고 있는 식용 및 미식용 선인장 22종에 대해 판크레아틱 리파아제의 활성 저해물질을 탐색하였고, 그 결과는 이하 표 11과 같았다. 즉 식용가능한 선인장의 경우 보검 및 대경, 금호에서 효소저해활성을 가진 것으로 나타났으며, 미식용으로는 당인 및 부용이 강한 지방분해효소 저해활성을 나타냈으며 그밖에 정야, 일월금, 연봉, 삼각주에서도 저해활성을 보여주었다(이하 표 11 참조).In this experiment, the activity inhibitors of pancreatic lipase were searched for 22 kinds of edible and gourmet cactus grown in Goyang City, and the results are shown in Table 11 below. In other words, edible cactus showed enzymatic inhibitory activity in bogeum, Daegyeong and Kumho, and showed strong inhibitory activity of lipolytic enzymes in sugar and bouillon for food use. Activity was shown (see Table 11 below).
[표 11] 판크레아틱 리파아제 저해활성 결과Table 11 Results of Pancreatic Lipase Inhibitory Activity
(월토이) Kalanchoe tomentosa
(Woltoys)
(불사조) Kalanchoe daigremontiana
(Phoenix)
(청솔) Chamaecereus silvestrii
(Cheongsol)
(십이지권) Haworthia fasciata
(Duodenum)
(삼각주) Hyloceruns trigonus
(delta)
(상기 표 11에서 "+++는 매우 강한 저해, ++ 강한 저해, + 저해, - 저해없음 " 을 나타낸다.)(In Table 11, "+++ represents very strong inhibition, ++ strong inhibition, + inhibition,-no inhibition.")
(3) 또한 그리고 1차 선정된 판크레아틴 리파아제 활성 저해 선인장의 저해능 확인은 Bitou 등의 방법에 따라 트리올레인(triolein)으로부터 분리되는 올레인산을 측정하였고, 그 결과는 다음의 도 3과 같았다(도 3의 Orlistat은 비만방지 의약품으로써 대조구로 실험에 이용하였다.). 선인장 중에서 보검 및 대경에서 판크레아틴 리파아제 활성 저해 효과가 나타났다(도 3 참조). (3) In addition, the inhibitory ability of the first selected pancreatin lipase activity inhibiting cactus was measured by oleic acid separated from triolein according to the method of Bitou et al., The results were as shown in FIG.
(4) 또한 기존에 시중에 유통되고 있는 천년초 및 백년초의 판크레아틱 리파아제 저해능을 확인하기 위하여 트리올레인(triolein)을 사용하여 본 연구에서 1차 선발된 보검 등과 비교 실험한 결과는 도 4와 같았다(도 4 참조). (4) In addition, in order to confirm the pancreatic lipase inhibitory ability of cheonnyeoncho and baeknyeoncho, which are currently on the market, using triolein (triolein) in the present study compared with the primary screening test results, etc. Was the same (see FIG. 4).
상기의 현재 시중에서 유통되고 있는 천연초 및 백년초 등에서는 판크레아틱 리파아제 저해능이 전혀 없는 것으로 나타났으며 오히려 지방 분해를 촉진시켜 지방의 흡수를 촉진시키는 성분이 존재하는 것으로 밝혀졌다. 따라서, 본 연구 결과에서 나타난 것처럼 보검 등을 이용한 지방분해 억제를 통한 비만 예방용식품의 개발이 가능하리라 판단된다. The natural vinegar and baeknyeoncho, which are currently in the market, have been shown to have no pancreatic lipase inhibitory activity. Rather, it has been found that there is an ingredient that promotes fat breakdown to promote fat absorption. Therefore, as shown in the results of this study, it would be possible to develop obesity-preventing foods by suppressing lipolysis using a test.
6. 피부 재생력 및 항염증 활성 실험6. Skin regeneration and anti-inflammatory activity experiment
(1) 본 실험에서는 세포에 선인장(보검, 대경, 금호, 화제) 추출물을 처리 후 western blot를 사용하여 COX-2의 억제에 의한 소염작용과 COX-2 발현에 따른 피부 재생력을 확인하였다. (1) In this experiment, after the cactus (bogeum, Daegyeong, Kumho, topical) extracts were treated to the cells, western blot was used to confirm anti-inflammatory action by inhibition of COX-2 and skin regeneration by COX-2 expression.
COX-2는 감염이나 상해 중에 혈관내피세포에서 생성되며, 세포의 지질인 아라키돈산(arachidonic acid)를 분해하여 열, 통증, 기타 불편한 염증증상을 유발하는 물질(프로스타글란딘)로 전환시킨다. Cyclooxygenase(COX)는 아라키돈산으로부터 프로스타글란딘(PG)들을 합성하는 효소이며, 이소폼으로는 COX-1과 COX-2가 존재한다. COX-1은 일정하게 발현되며, COX-2는 inducible form으로 COX-2는 염증이 있는 곳이나 대장, 직장암 및 그 외에도 여러 가지 상피 세포 암에서 그 발현이 증가되어 있다. COX-2 is produced in vascular endothelial cells during infection or injury and breaks down the cell's lipid, arachidonic acid, into a substance (prostaglandin) that causes fever, pain, and other uncomfortable inflammation. Cyclooxygenase (COX) is an enzyme that synthesizes prostaglandins (PG) from arachidonic acid, and isoforms include COX-1 and COX-2. COX-1 is constantly expressed, and COX-2 is an inducible form, and COX-2 is increased in inflammation, colon, rectal cancer, and other epithelial cell cancers.
COX-2는 암을 포함한 세포의 성장 및 분화와 연관된 각종 퇴행성 질환의 발병과 진행에 중요한 역할을 하며, 과 발현에 의해 암 조직에서의 혈관신생 및 전이능이 높아지고 apoptosis를 막는다는 점과 COX-2의 특이적 저해제에 의한 angiogenesis와 종양형성의 억제 등의 결과에서 이 유전자의 선택적 조절에 의한 암 예방 전략이 대두되고 있다. COX-2 plays an important role in the development and progression of various degenerative diseases associated with the growth and differentiation of cells, including cancer, and overexpression increases angiogenesis and metastasis in cancer tissues and prevents apoptosis. Inhibition of angiogenesis and tumorigenesis by specific inhibitors has led to cancer prevention strategies by selective regulation of this gene.
한편 암 뿐만 아니라 면역계 질환, 심혈관 질환, 당뇨 등과 관련된 유전자의 promoter 영역에 결합하여 그들의 유전자발현을 유도하는 nuclear factor kappa B에 의하여 COX-2 발현이 조절된다는 보고들에서도 COX-2의 중요성을 잘 알 수 있다. 따라서 COX-2의 최근 연구 방향은 이러한 전사활성 요소와 연관된 상위 신호전달 경로에 많은 관심이 모아지고 있으며 이들의 활성을 조절할 수 있는 물질의 탐색작업에 많은 비중을 두고 있다. COX-2 expression is also well understood in the reports that COX-2 expression is regulated by nuclear factor kappa B, which binds to promoter regions of genes related to immune system diseases, cardiovascular disease, diabetes, and induces their gene expression as well as cancer. Can be. Therefore, the recent research direction of COX-2 has attracted much attention on the upstream signaling pathways associated with these transcriptional activation elements and places much emphasis on the search for substances that can regulate their activity.
그러나 다른 관점에서 볼 때 즉, 세포의 성장 및 분화와 연관해서 볼 때 cox-2의 level이 증가 되어있다는 것은 세포생존과 세포성장이 촉진된다는 것이다. 예를 들어 궤양이란 소화기를 이루는 식도, 위 십이지장, 소장, 대장, 직장을 포함한 전 소화기 계통의 내벽에 구멍이 난 것을 말하며, 어느 곳에서 생겼나에 따라 다르게 되는데 주로 식도궤양, 위궤양, 십이지장궤양으로 나누어지게 된다. 비스테로이드계 소염제인 asprine, mortrin, aleve와 같은 진통제는 화학적 또는 외적인 손상으로부터 내벽을 보호하는 물질인 프로스타글란딘의 생성에 필요한 cycolooxygenease 생산을 억제하는 역할을 한다. 이 물질 생산이 저하되면서 위산이 위벽을 부식시키고 궤양을 일으키게 된다. 즉, 위궤양 치료의 분자생물학적 mechanism에서 cox-2는 위 분비기관의 복구와 상피세포의 증식에 중요하다.In other respects, however, increased levels of cox-2, in relation to cell growth and differentiation, promote cell survival and cell growth. For example, an ulcer is a hole in the inner wall of the entire digestive system, including the esophagus, stomach duodenum, small intestine, large intestine, and rectum, which makes up the digestive system, and varies depending on where it occurs. You lose. Painkillers such as asprine, mortrin, and aleve, which are nonsteroidal anti-inflammatory drugs, inhibit the production of cycolooxygenease for the production of prostaglandins, a material that protects the inner wall from chemical or external damage. As the production of these substances decreases, acid can erode the stomach walls and cause ulcers. In other words, cox-2 is important for gastric ulcer repair and epithelial cell proliferation.
(2) 본 실험에서는 보검의 추출물의 처리가 도 5와 같이 COX-2의 분비를 촉진시켜 외상으로 인한 상피세포의 회복에 도움을 줄 수 있는 것으로 나타났다. 따라서 기존의 선인장이 항염증 작용을 나타내는 것(COX-2의 억제)과는 다른 작용으로 세포성장을 촉진시켜 위궤양 등의 궤양치료제로서의 사용 가능성을 알 수 있었다(도 5 참조). (2) In this experiment, it was shown that the treatment of the extract of bogeum can help the recovery of epithelial cells due to trauma by promoting the secretion of COX-2 as shown in FIG. Therefore, the existing cactus promotes cell growth by a different action from the anti-inflammatory action (inhibition of COX-2), it can be seen that the use as a therapeutic agent for ulcers such as gastric ulcers (see Fig. 5).
7. 항 당뇨 및 혈전용해 활성 실험7. Antidiabetic and Thrombolytic Activity Test
(1) 항 당뇨활성은 장에서의 포도당(glucose) 생성을 억제시켜 체내 흡수를 저해하는 능력을 확인하는 것으로 α-glucosidase활성 저하능을 측정하였다. 그리 고 혈전 용해활성 측정은 피브리노겐(Fibrinogen)(Sigma 4883) 및 트롬빈(Thrombin)(녹십자, 동결건조분말, 5,000 IU), 아가로오즈(agarose)를 사용하여 Haverkate와 Trass방법(1974)에 따라 fibrin plate를 제조한 후 다음과 같이 실험하였다.즉, 0.2% fibrinogen용액(pH 7.5인 borate saline buffer로 제조) 5㎖를 혼합하여 제조한 fibrinogen-agarose 용액에 thrombin 50㎕를 첨가하여 fibrin plate를 제조하였다. Plate에 지름 5mm의 pasteur pipette로 4개 원형을 만들어 각 시료를 20㎕씩 농도별로 점적하고 37℃에서 18시간 동안 반응시킨 다음, 효소에 의해 fibrin 막이 용해되어 생성된 clear zone의 크기를 측정하였다. (1) Anti-diabetic activity was determined to inhibit the production of glucose by inhibiting glucose (glucose) production in the intestine and measured the ability to lower α-glucosidase activity. And Thrombolytic activity was measured by fibrinogen (Fibrinogen) (Sigma 4883), Thrombin (Green Cross, Lyophilized Powder, 5,000 IU), and agarose using fibrin plate according to Haverkate and Trass method (1974). After the preparation, the test was performed as follows. That is, fibrin plates were prepared by adding 50 μl of thrombin to a fibrinogen-agarose solution prepared by mixing 5 ml of a 0.2% fibrinogen solution (prepared with a borate saline buffer of pH 7.5). Four rounds of pasteur pipettes with a diameter of 5 mm were made on the plate, and 20 μl of each sample was dipped at each concentration and reacted at 37 ° C. for 18 hours.
(2) 식용 가능한 보검 및 대경, 금호 추출물의 경우 α-glucosidase활성 저하 활성에 따른 항 당뇨활성이 없는 것으로 나타났으며, 혈전용해 활성도 없는 것으로 나타났다.(2) Edible gums, Daekyeong, and Kumho extracts showed no antidiabetic activity due to α-glucosidase deactivation activity and no thrombolytic activity.
<실험예 2> 선인장 추출물을 포함하는 기능성 음료조성물의 관능검사Experimental Example 2 Sensory Test of Functional Drink Composition Containing Cactus Extract
(1) 상기의 실시예 4-27을 이용하여 제조된 음료조성물을 이용하여 이하의 실험에서는 선인장 추출물을 함유하는 음료조성물의 최적 배합비 설정을 위한 기호도 검사를 하였다.(1) In the following experiment using the beverage composition prepared using the above Example 4-27, the palatability test for setting the optimum blending ratio of the beverage composition containing the cactus extract was examined.
이하의 기호도 검사(관능검사)는 관능검사의 유경험자 20명을 선정하여 수행되었고, 9점 척도법을 기준으로 이들 20명의 기호도 점수를 평균하여 소수점 이하 자리는 반올림 하여 구한 값을 기준으로 하였다(이하 표 12 참조).The following palatability test (Sensory test) was performed by selecting 20 experienced subjects of sensory test. Based on the 9-point scale method, these 20 palatability scores were averaged and rounded to the nearest decimal place. 12).
[표 12] 관능검사 결과[Table 12] Sensory Test Results
포함 음료Kumho Extract
Drink included
(2) 상기 표 12에서 알 수 있듯이 보검 추출물의 경우 실시예 4의 방법으로 제조된 음료조성물이 가장 기호도가 높았다. 따라서 최적의 보검 추출물과 액상과당의 첨가함량을 알 수 있었다. 또한 대경 추출물의 경우 실시예 12 및 실시예 15의 방법으로 제조된 음료조성물이 가장 기호도가 높았다. 따라서 최적의 대경 추출물과 액상과당의 첨가함량을 알 수 있었다. 또한 금호 추출물의 경우 실시예 20의 방법으로 제조된 음료조성물이 가장 기호도가 높았다는 것을 알 수 있었다.(2) As can be seen in Table 12, in the case of bogeum extract, the beverage composition prepared by the method of Example 4 had the highest preference. Therefore, the optimal content of bogeum extract and liquid fructose was found. In addition, the beverage composition prepared by the method of Example 12 and Example 15 in the case of large diameter extract had the highest preference. Therefore, the optimum content of large diameter extract and liquid fructose was found. In addition, the case of Kumho extract was found that the beverage composition prepared by the method of Example 20 had the highest preference.
본 발명은 유용한 기능을 가지는 선인장의 효능을 밝히고 선인장 추출물의 제조방법 및 이를 이용한 기능성 음료를 제공하여, 새로운 식품산업에의 이윤창출과 수출촉진에도 기여할 것으로 기대된다. 또한 선인장 육종 종사자들의 의욕을 고취시키며, 일반 소비자들이 영양성 높고 맛도 좋은 선인장 추출물을 포함한 식품을 다양하게 섭취하게 하여 국민생활건강에도 이바지 할 것으로 기대된다.The present invention is expected to reveal the efficacy of the cactus having a useful function and to provide a method for producing a cactus extract and a functional beverage using the same, to contribute to profit creation and export promotion to a new food industry. In addition, it is expected to contribute to national health by inspiring cactus breeders and encouraging consumers to eat a variety of foods including nutritious and tasty cactus extracts.
도 1은 살모넬라 티피무리움(Salmonella typhimurium) TA98 및 살모넬라 티피무리움 TA100에 대한 선인장 추출물의 복귀 돌연변이 수를 나타낸다. 1 shows the number of return mutations of the cactus extract for Salmonella typhimurium TA98 and Salmonella typhimurium TA100.
도 2는 선인장 추출물의 전자공여활성을 나타낸다.2 shows the electron donating activity of the cactus extract.
도 3은 트리올레인(Triolein)을 이용한 선인장 추출물의 판크레아틱 리파아제의 저해능을 나타낸다.Figure 3 shows the inhibitory ability of pancreatic lipase of the cactus extract using Triolein (Triolein).
도 4는 천년초(뿌리, 줄기, 열매) 및 백년초(줄기)와 보검, 당인 추출물의 판크레아틱 리파아제의 저해능을 나타낸다. Figure 4 shows the inhibitory ability of pancreatic lipase of cheonnyeoncho (root, stem, fruit) and baeknyeoncho (stem) and bogeum, sugar extract.
도 5는 선인장 추출물의 처리에 따른 COX-2의 발현정도를 나타낸다.Figure 5 shows the expression level of COX-2 according to the treatment of the cactus extract.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080130097A KR101139262B1 (en) | 2008-12-19 | 2008-12-19 | Healthy food composition containing the cactus extract for non-toxic, antioxidant active and antiobese active |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080130097A KR101139262B1 (en) | 2008-12-19 | 2008-12-19 | Healthy food composition containing the cactus extract for non-toxic, antioxidant active and antiobese active |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100071397A true KR20100071397A (en) | 2010-06-29 |
KR101139262B1 KR101139262B1 (en) | 2012-05-14 |
Family
ID=42368905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080130097A KR101139262B1 (en) | 2008-12-19 | 2008-12-19 | Healthy food composition containing the cactus extract for non-toxic, antioxidant active and antiobese active |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101139262B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180079023A (en) * | 2016-12-30 | 2018-07-10 | 주식회사 풀무원 | Composition for preventing, treating or improving metabolic syndrome comprising mixture of chia seeds and cactus an active ingredient |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101272568B1 (en) | 2011-03-22 | 2013-06-10 | 권용덕 | Water for boiling Rice and The manufacturing Method thereof |
KR101388679B1 (en) * | 2013-12-05 | 2014-04-24 | 주식회사 삼양제넥스 | Gummy food composition containing royal jelly and method for preparing the same |
KR101709246B1 (en) | 2014-05-30 | 2017-02-22 | 일동후디스 주식회사 | Anti-obesity synbiotics composition with Laminaria and lactic acid bacteria complex |
KR101578070B1 (en) * | 2015-04-08 | 2015-12-16 | 김경일 | Health supplementing food for enhancing hair restoration, alleviating and improving hair loss, adjusting blood sugar, alleviating and improving gastrointestinal disorders |
KR20240036239A (en) | 2022-09-13 | 2024-03-20 | 호서대학교 산학협력단 | Composition for antioxidant, skin regeneration with Crassula Buddha's Temple extract as an active ingredient |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050097465A (en) * | 2005-08-25 | 2005-10-07 | (주)케어메딕스 | Extracts from opuntia ficus having the effect on eliminating a hangover and improving the liver function |
KR101164020B1 (en) * | 2006-09-29 | 2012-07-18 | 한국과학기술연구원 | Pharmaceutical composition comprising an extract from Opuntia ficus-indica |
-
2008
- 2008-12-19 KR KR1020080130097A patent/KR101139262B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180079023A (en) * | 2016-12-30 | 2018-07-10 | 주식회사 풀무원 | Composition for preventing, treating or improving metabolic syndrome comprising mixture of chia seeds and cactus an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR101139262B1 (en) | 2012-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shai et al. | Yeast alpha glucosidase inhibitory and antioxidant activities of six medicinal plants collected in Phalaborwa, South Africa | |
Mohanraj et al. | Sweet potato (Ipomoea batatas [L.] Lam)-A valuable medicinal food: A review | |
Alara et al. | Carica papaya: comprehensive overview of the nutritional values, phytochemicals and pharmacological activities | |
KR101139262B1 (en) | Healthy food composition containing the cactus extract for non-toxic, antioxidant active and antiobese active | |
Jyothirmayi et al. | Banana medicinal uses | |
Panghal et al. | Cnidoscolus aconitifolius: Nutritional, phytochemical composition and health benefits–A review | |
Shubhashree et al. | Therapeutic and nutritional values of Narikelodaka (tender coconut water)-A review | |
KR100236454B1 (en) | Low molecular weight vegetable composition | |
KR101965061B1 (en) | Composition for prevention or treatment of metabolic disorder comprising peanut sprout extracts and fractions thereof | |
Nouman et al. | Phytochemical profiling of curry (Murraya koenijii) leaves and its health benefits. | |
CN104093411A (en) | Composition containing chlorella extract for the prevention or treatment of liver disorders | |
KR101056779B1 (en) | Brewed vinegar prepared using the cactus extract and the source containing the brewed vinegar and a method for producing the same | |
Hussain et al. | Comparative in vitro analysis of anti-diabetic activity of Indo-Pak black cardamom (Amomum subulatum Roxb.) and Chinese black cardamom (Amomum tsao-ko Crevost et Lemaire) | |
KR20100071781A (en) | Preparing method of cactus powder, fuctional food using the same cactus powder and preparing method thereof | |
Handayani et al. | Kecombrang (Etlingera elatior) Leaves Ethanol Extract Effect to Lens and Erythrocyte Aldose Reductase Activity in Wistar strain white rats (Rattus norvegicus) Streptozotocin induced | |
Ma et al. | Extraction optimization of total phenolics from Thai basil (Ocimum basilicum var. thyrsiflora) leaves and bioactivities of the extract | |
Feresin et al. | Tree Berries | |
KR102653686B1 (en) | Food composition for alleviating swelling through detoxification and detoxification effects | |
KR101532307B1 (en) | Pharmaceutical compositions having anti-metastasis activity comprising extract of bambusae caulis in taeniam | |
KR102295725B1 (en) | Meal substitute for liver protection based on sweet potato and a method for manufacturing the same | |
KR101104269B1 (en) | Pharmaceutical composition comprising the extract from Iris nertschinskia for preventing and treating cancer | |
KR101911628B1 (en) | The method of preparing a counteractive using medicinal stuff plant | |
Bhasin | Exploring the versatile potential of garden cress seeds: Therapeutic applications and industrial utilization: A comprehensive review | |
Lim | Ficus carica | |
Mekonnen | ENZYMATIC AND ANTI MICROBIAL ACTIVITY OF PAPAYA (Carica papaya L.) LEAF, SEED AND FRUIT PULP EXTRACTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150213 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160308 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |